4.7 Article

Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis

期刊

DIABETES CARE
卷 44, 期 2, 页码 578-585

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dc20-1857

关键词

-

资金

  1. National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [UL1TR002378]
  2. NIH [1K23GM128221-01A1, P30DK111024, P30DK111024-05S1, U30 P30DK11102]
  3. Novo Nordisk
  4. AstraZeneca
  5. Dexcom
  6. Merck

向作者/读者索取更多资源

Diabetes and hyperglycemia are important risk factors for poor outcomes in hospitalized COVID-19 patients. The study found that both hyperglycemia and hypoglycemia were associated with increased mortality. Admission glucose level was a strong predictor of death in patients directly admitted to the ICU, while severe hyperglycemia after admission was a strong predictor of death in non-ICU patients.
OBJECTIVE Diabetes and hyperglycemia are important risk factors for poor outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19). We hypothesized that achieving glycemic control soon after admission, in both intensive care unit (ICU) and non-ICU settings, could affect outcomes in patients with COVID-19. RESEARCH DESIGN AND METHODS We analyzed pooled data from the Glytec national database including 1,544 patients with COVID-19 from 91 hospitals in 12 states. Patients were stratified according to achieved mean glucose category in mg/dL (<= 7.77, 7.83-10, 10.1-13.88, and >13.88 mmol/L; <= 140, 141-180, 181-250, and >250 mg/dL) during days 2-3 in non-ICU patients or on day 2 in ICU patients. We conducted a survival analysis to determine the association between glucose category and hospital mortality. RESULTS Overall, 18.1% (279/1,544) of patients died in the hospital. In non-ICU patients, severe hyperglycemia (blood glucose [BG] >13.88 mmol/L [250 mg/dL]) on days 2-3 was independently associated with high mortality (adjusted hazard ratio [HR] 7.17; 95% CI 2.62-19.62) compared with patients with BG <7.77 mmol/L (140 mg/dL). This relationship was not significant for admission glucose (HR 1.465; 95% CI 0.683-3.143). In patients admitted directly to the ICU, severe hyperglycemia on admission was associated with increased mortality (adjusted HR 3.14; 95% CI 1.44-6.88). This relationship was not significant on day 2 (HR 1.40; 95% CI 0.53-3.69). Hypoglycemia (BG <70 mg/dL) was also associated with increased mortality (odds ratio 2.2; 95% CI 1.35-3.60). CONCLUSIONS Both hyperglycemia and hypoglycemia were associated with poor outcomes in patients with COVID-19. Admission glucose was a strong predictor of death among patients directly admitted to the ICU. Severe hyperglycemia after admission was a strong predictor of death among non-ICU patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据